The BLA is seeking FDA approval of linvoseltamab for the treatment of relapsed/refractory (R/R) multiple myeloma (MM ... with the global sales of both drugs. Regeneron currently carries a Zacks ...

Early intervention in high-risk smoldering myeloma with lenalidomide delays progression by up to 7 years and achieves ...

Regeneron’s bid to join the market for BCMA-targeted bispecific antibodies for multiple myeloma is nearing a conclusion, with the FDA starting a priority review of its linvoseltamab drug candidate.

Regeneron’s bispecific antibody linvoseltamab has received conditional approval from the European Commission (EC) for use in relapsed or refractory multiple myeloma. The decision comes just eight ...

The BLA is seeking FDA approval of linvoseltamab for the treatment of relapsed/refractory (R/R) multiple myeloma (MM) that has progressed after at least three prior therapies. Regeneron stated ...

Regeneron Pharmaceuticals ... study on oncology drug linvoseltamab. LINKER-MM2 is a phase Ib, open-label clinical trial evaluating linvoseltamab in combination with other cancer treatments in patients ...